id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-263055-4f25h9l4	Fogarty, Helen	More on COVID‐19 coagulopathy in Caucasian patients	2020-05-25		.txt	text/plain	1191	67	39	We are grateful for the comments of Marrietta et al, [1] and welcome the opportunity to provide further details on the coagulopathy observed in our patients with COVID-19 infection [2]. The weight-adjusted low molecular weight heparin (LMWH) thromboprophylaxis used in the study is that routinely used for hospital in-patients in our institution, consistent with national recommendations [3,4] With respect to the cohort of patients with COVID-19 enrolled in our study, it is important to highlight that 74% of patients received enoxaparin 40mg (4000 IU) subcutaneously once daily. This hypothesis is supported by emerging data suggesting that the incidence of thrombotic complications in critically ill patients with COVID-19 may be >30%, even in patients receiving LMWH thromboprophylaxis. From the literature, it is clear that other centres have already elected to institute increased LMWH doses for selected patients with severe COVID-19 infection.	./cache/cord-263055-4f25h9l4.txt	./txt/cord-263055-4f25h9l4.txt